Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ajovy

AstraZeneca AZ

AZ gets US approval for Veltassa rival Lokelma

But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia

- PMLiVE

Allergan’s oral migraine drug closer to US filing

New data keeps Allergan ahead of rival Biohaven

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

- PMLiVE

EMA set to review Teva’s migraine injection

Fremanezumab could be approved for prophylactic use of migraines

AstraZeneca AZ

AZ gets EMA green light for severe asthma drug Fasenra

The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero

- PMLiVE

Teva cuts 25% of workforce, with Israel taking a heavy toll

But share prices increase by almost 14%

- PMLiVE

Teva sheds R&D chief after new CEO takes the helm

Kåre Schultz begins remoulding the Israeli pharma firm

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

Teva faces early rival to longer-acting Copaxone in US

US regulator approves Mylan’s MS drug

Teva’s Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role

- PMLiVE

Teva offloads women’s health unit in quickfire deals

The Israeli pharma group is also set to sell its oncology and pain business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links